Dexmedetomidine and Vasopressin in Septic Shock - Trial NCT06302998
Access comprehensive clinical trial information for NCT06302998 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mansoura University and is currently Not yet recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 260 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mansoura University
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jan 01, 2026
Primary Outcome
in-hospital mortality
Summary
Rudiger and Singer suggested strategies for refining adrenergic stress
 (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce
 the catecholamine load during sepsis. The investigators will use vasopressin as the primary
 vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.
 
 The investigators of the current study will use DEXPRESSIN in septic shock patients to
 investigate the effects of decatecholaminization on in-hospital mortality.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06302998
Non-Device Trial